2311 Green Road, Suite A, Ann Arbor, Michigan 48105


Biological pharmaceutical development company, founded by James R. Baker Jr. and Ted Annis in 2000 as a spin-out from the Center for Biologic Nanotechnology at the University of Michigan.

In the trade press

Ann Arbor-based NanoBio Corp. Monday announced an initiative to develop an intranasal vaccine for the treatment of hepatitis B. NanoBio and the University of Michigan’s Michigan Nanotechnology Institute for Medicine and Biological Sciences received funding through a Phase 1 Small Business Technology Transfer grant from the National Institutes of Health to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients.

"The new claims circumscribe all of NanoBio’s anti-infective and dermatological products, as well as our intranasal and intramuscular vaccine adjuvants,” NanoBio CEO and founder James Baker said in a statement.

NanoBio Corp., a University of Michigan spinoff that has several pharmaceutical products in various stages of testing, announced Wednesday that it has closed on an investment round of $10 million, capping its series B round of funding at $22 million.

The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and an inactivated pathogen or protein derived from the pathogen. The present invention thus provides improved vaccines against a variety of environmental and human-released pathogens.